Bullous pemphigoid (BP) is an autoimmune blistering disorder of the skin. Various provocative factors have been proposed. However, BP in renal transplantation patients has scarcely been reported. Herein, we report the case of a 27-year-old man who received cadaveric renal transplantation 10 years ago presenting with bullous eruption during chronic renal allograft rejection phase, with the renal allograft being the possible trigger stimulus for BP development in our case. Bullous lesions were soon controlled by oral corticosteroids and did not recur after removal of the graft. The pathogenesis and management of such patients will also be reviewed along with the case report.
Introduction
Bullous pemphigoid (BP) is an acquired autoimmune blistering dermatosis with clinical features of chronic, recurrent subepidermal bulla formation. Various provocative factors, including cancers, drugs, physical stimuli, and immune abnormalities, have been proposed. 1, 2 However, BP in renal transplantation patients is rare. We report a case of chronic renal allograft rejection presenting with BP and discuss the pathogenesis and management.
Case report
A 27-year-old man had end-stage renal failure because of longterm Chinese herbal medication use and received left nephrectomy with ambulatory peritoneal dialysis from 1997 to 1999. He then received cadaveric renal transplantation in Mainland China in December 1999. However, progressive deterioration of renal function was noted thereafter despite the use of immunosuppressants, which included prednisolone, mycophenolate mofetil, sirolimus, and tacrolimus. Renal allograft biopsy showed chronic rejection change. He then received hemodialysis regularly and furosemide treatment for controlling fluid overload. Other significant medical history included hypertension under oral medication control. One month before the beginning of bullous eruption, hematuria along with generalized pruritus and tiny erythematous papules and vesicles were noted during the tapering of oral prednisolone (2.5 mg/d) and tacrolimus (2 mg/d). Subsequently, large tense bullae progressively emerged over his trunk and four limbs with oozing erosive wounds (Figure 1 ), and he was admitted to our dermatology ward for further treatment. At admission, serum creatinine was 6.94 mg/dL with blood urea nitrogen of 21.8 mg/dL. Complete blood count and differential count showed marked eosinophilia (eosinophil count, 13.4%) without leukocytosis. Liver function tests, general serum biochemical tests, electrolytes, stool routine, chest X-ray were all normal. A skin biopsy was performed on the patient's right forearm for histology and direct immunofluorescence study, which showed a subepidermal blister with many eosinophils in the superficial dermis (Figures 2A and 2B ) and linear immunoglobulin G (IgG) and complement component 3 deposition along the dermoepidermal junction ( Figures 3A and 3B) , respectively. However, indirect immunofluorescence study result was negative. Immunohistochemical staining with Type IV collagen showed that Type IV collagen was localized to the blister base ( Figure 2C ). According to the clinical pictures, pathology findings, immunofluorescence study, and Type IV collagen immunohistochemical staining, BP was diagnosed. Oral prednisolone (30 mg/d) was administered for controlling the disease activity. Bullous lesions soon resolved after treatment without formation of new blisters. Hematuria disappeared once corticosteroids were administered. Itching improved dramatically as well.
After discharge, oral prednisolone was gradually tapered. Before the onset of bullous eruption, a cauliflower-like lesion was noted on the neck of his bladder from cystoscopy examination during the survey for hematuria. After improvement of skin lesions, the right kidney, allograft, and bladder tumor were removed. Histopathology of the renal graft was compatible with chronic rejection. Direct immunofluorescence study of the renal allograft showed faint and barely detectable IgG deposition. No bullous eruption recurred in the subsequent 8 months after graft nephrectomy and discontinuation of both systemic corticosteroids and immunosuppressants. The patient is now under regular hemodialysis.
Discussion
BP is a chronic autoimmune subepidermal blistering dermatosis mediated by autoantibodies against antigens located in the basement membrane zone. BP in renal transplantation patients is rare, and only six cases have been described in the published literature.
3e8 A summary of previously reported cases and ours is given in Table 1 . Almost all the reported patients had chronic renal allograft rejection, with BP responding partially to systemic corticosteroid treatment. 3e7 Skin lesions in two cases cleared after removal of the graft. 3, 6 These observations suggested to us that renal allograft may play an important role in the pathogenesis of BP. In our case, generalized itching and bullous eruption occurred concomitantly with hematuria and during the tapering of immunosuppressants for renal allograft rejection, resolving simultaneously after systemic corticosteroid treatment. BP did not recur after graft nephrectomy, supporting the supposition that renal allograft participates in the pathogenesis of BP. Moreover, during the tapering of immunosuppressants, graft rejection triggered an overwhelming response to allograft antigens with formation of autoantibodies. Administration of corticosteroids helped to alleviate the rejection as well as the autoimmune process, and we believe that further graft nephrectomy helped to eliminate the source of autoantibody induction. The immune mechanism producing bullous eruption during renal graft rejection is not fully understood so far. One theory is de novo autoantibody formation, which, in renal allografts, may result from chronic allogeneic stimuli. 9 Immune cross-reactivity between the glomerular and epidermal basement membrane (one possible antigen being identified as the alpha 5 chain of Type IV collagen) 10 has been suggested in some of the reported cases of BP in association with graft rejection, 11e15 explaining the possible association between BP and hematuria in our patient. We also observed a different direct immunofluorescence result in the renal allograft compared with other case reports, with faint and barely detectable IgG deposition, which may be a result of endstage graft damage with minimal antigens left in the allograft.
Currently, both cellular and humoral immunities are believed to play an important role in the development of chronic renal allograft rejection. 16e19 In experimental models for chronic renal allograft rejection, antibodies against glomerular basement membrane antigens have been found, including the heparan sulfate proteoglycan perlecan and collagen Types IV and VI. 20, 21 Crossreactive autoantibodies against both renal allograft and skin antigens may explain the development of BP in a patient experiencing renal allograft rejection. BP has been reported to be associated with some medications. Sulfur-containing drugs, such as furosemide, 22 commonly cause drug-induced BP, and may act as hapten, altering the antigenicity of the basement membrane zone or attaching to cells and eliciting the formation of autoantibodies. Tacrolimus, a selective blocker for the expression of the interleukin-2 gene, is believed to act on a key element of the immune system, possibly on the regulatory T cells, causing a decreased regulatory T-cell activity indirectly contributing to the induction of autoantibodies. Because our patient had been treated with both furosemide and tacrolimus for many years, it is less likely that BP was induced by drugs. Systemic corticosteroids, plasmapheresis, monoclonal antibody, 23 intravenous immunoglobulin, 24, 25 and graft nephrectomy have all been used in the treatment of BP patients with allograft rejection. Because a unified therapeutic approach for these patients is absent because of the rarity of cases and lack of experience of most clinicians, there is a need for the establishment of a standardized treatment protocol for these patients.
In conclusion, we report a case of BP associated with chronic renal allograft rejection in a young man with renal allograft, the probable triggering factor for the development of the bullous disease. Bullous eruption was easily controlled by systemic corticosteroids and did not recur after graft nephrectomy during a clinical follow-up of 8 months. For the treatment of BP patients with chronic renal allograft rejection, in addition to the elimination of all possible provocative factors, systemic corticosteroids with graft nephrectomy can be considered as a therapeutic option.
